TY - JOUR
T1 - Pregnancy vitamin D supplementation and offspring bone mineral density in childhood: Follow-up of a randomised controlled trial
AU - Moon, Rebecca J.
AU - D'Angelo, Stefania
AU - Curtis, Elizabeth M.
AU - Ward, Kate A.
AU - Crozier, Sarah R.
AU - Schoenmakers, Inez
AU - Javaid, M. Kassim
AU - Bishop, Nicholas J.
AU - Godfrey, Keith M.
AU - Cooper, Cyrus
AU - Harvey, Nicholas C.
AU - the MAVIDOS Trial Group
AU - Dennison, Elaine M.
AU - Eastell, Richard
AU - Fraser, Robert
AU - Gandhi, Saurabh V.
AU - Inskip, Hazel M.
AU - Kennedy, Stephen H.
AU - Papageorghiou, Aris T.
AU - Prentice, Ann
N1 - Data sharing plan: Data described in the manuscript, code book, and analytic code will be made available upon request pending application to and approval by the trial steering committee. Proposals should be directed to [email protected]. To gain access, data requestors will need to sign a data access agreement.
Rights Retention Statement: For the purpose of Open Access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.
Funding information: This work was supported by Versus Arthritis UK (17702), Medical Research Council [MC_PC_21003; MC_PC_21001], Bupa Foundation, and National Institute for Health and Care Research National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, and NIHR Biomedical Research Centre, University of Oxford. IS and AP were funded by the Medical Research Council (MRC) (programme code U105960371). RM and EMC are/were supported by NIHR Academic Clinical Lectureships. EMC was supported by a Wellcome Trust Clinical Research Fellowship. KMG is supported by the NIHR (NIHR Senior Investigator NF-SI-0515-10042) and Alzheimer’s Research UK (ARUK-PG2022A-008. The work leading to these results was supported by the European Union's Seventh Framework Programme (FP7/2007-2013), projects EarlyNutrition and ODIN under grant agreements numbers 289346 and 613977. We are extremely grateful to Merck GmbH for the kind provision of the Vigantoletten supplement. Merck GmbH had no role in the trial execution, data collection, analysis or manuscript preparation. The original protocol incorporated suggestions from the Arthritis Research UK Clinical Trials Collaboration. The funders had no other role in the study and the corresponding author had full access to all of the data and the final responsibility to submit for publication.
PY - 2024/9/19
Y1 - 2024/9/19
N2 - Background: Findings from the MAVIDOS trial demonstrated a positive effect of gestational cholecalciferol supplementation on offspring bone mineral density (BMD) at age 4 years. Demonstrating persistence of this effect is important to understanding whether maternal vitamin D supplementation could be a useful public health strategy to improving bone health. Objective: We investigated whether gestational vitamin D supplementation increases offspring BMD at 6-7 years in an exploratory post-hoc analysis of an existing trial. Methods: In the MAVIDOS randomised controlled trial, pregnant females. Results: 454 children were followed up at age 6-7 years, of whom 447 had a usable DXA scan. Gestational cholecalciferol supplementation resulted in higher WBLH BMC (0.15 SD, 95%CI 0.04, 0.26), BMD (0.18 SD, 95%CI 0.06,0.31), BMAD (0.18 SD, 95%CI 0.04,0.32) and lean mass (0.09 SD, 95%CI 0.00,0.17) compared to placebo. The effect of pregnancy cholecalciferol on bone outcomes was similar at ages 4 and 6-7 years. Conclusions and relevance: Supplementation with cholecalciferol 1000 IU/day during pregnancy resulted in greater offspring BMD and lean mass in mid-childhood versus placebo in this exploratory post-hoc analysis. These findings suggest that pregnancy vitamin D supplementation may be an important population health strategy to improve bone health.
AB - Background: Findings from the MAVIDOS trial demonstrated a positive effect of gestational cholecalciferol supplementation on offspring bone mineral density (BMD) at age 4 years. Demonstrating persistence of this effect is important to understanding whether maternal vitamin D supplementation could be a useful public health strategy to improving bone health. Objective: We investigated whether gestational vitamin D supplementation increases offspring BMD at 6-7 years in an exploratory post-hoc analysis of an existing trial. Methods: In the MAVIDOS randomised controlled trial, pregnant females. Results: 454 children were followed up at age 6-7 years, of whom 447 had a usable DXA scan. Gestational cholecalciferol supplementation resulted in higher WBLH BMC (0.15 SD, 95%CI 0.04, 0.26), BMD (0.18 SD, 95%CI 0.06,0.31), BMAD (0.18 SD, 95%CI 0.04,0.32) and lean mass (0.09 SD, 95%CI 0.00,0.17) compared to placebo. The effect of pregnancy cholecalciferol on bone outcomes was similar at ages 4 and 6-7 years. Conclusions and relevance: Supplementation with cholecalciferol 1000 IU/day during pregnancy resulted in greater offspring BMD and lean mass in mid-childhood versus placebo in this exploratory post-hoc analysis. These findings suggest that pregnancy vitamin D supplementation may be an important population health strategy to improve bone health.
U2 - 10.1016/j.ajcnut.2024.09.014
DO - 10.1016/j.ajcnut.2024.09.014
M3 - Article
JO - American Journal of Clinical Nutrition
JF - American Journal of Clinical Nutrition
SN - 0002-9165
ER -
